Structure Therapeutics Inc. (GPCR)
NASDAQ: GPCR · Real-Time Price · USD
90.37
-1.50 (-1.63%)
At close: Jan 23, 2026, 4:00 PM EST
90.47
+0.10 (0.11%)
After-hours: Jan 23, 2026, 7:53 PM EST
Structure Therapeutics Employees
Structure Therapeutics had 218 employees as of September 30, 2025. The number of employees increased by 70 or 47.30% compared to the same quarter last year.
Employees
218
Change
70
Growth
47.30%
Revenue / Employee
n/a
Profits / Employee
-$966,445
Market Cap
6.25B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 218 | 70 | 47.30% |
| Jun 30, 2025 | 199 | 63 | 46.32% |
| Mar 31, 2025 | 183 | 72 | 64.86% |
| Dec 31, 2024 | 163 | 70 | 75.27% |
| Sep 30, 2024 | 148 | 61 | 70.11% |
| Jun 30, 2024 | 136 | 59 | 76.62% |
| Mar 31, 2024 | 111 | 43 | 63.24% |
| Dec 31, 2023 | 93 | 25 | 36.76% |
| Sep 30, 2023 | 87 | 15 | 20.83% |
| Jun 30, 2023 | 77 | 5 | 6.94% |
| Mar 31, 2023 | 68 | - | - |
| Dec 31, 2022 | 68 | - | - |
| Sep 30, 2022 | 72 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,769 |
| PTC Therapeutics | 939 |
| ImmunityBio | 673 |
| Crinetics Pharmaceuticals | 437 |
| Vaxcyte | 414 |
| CRISPR Therapeutics AG | 393 |
| Immunovant | 362 |
| Rhythm Pharmaceuticals | 283 |
GPCR News
- 4 days ago - Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s - CNBC
- 6 weeks ago - Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs - GlobeNewsWire
- 6 weeks ago - Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants - GlobeNewsWire
- 6 weeks ago - Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade) - Seeking Alpha
- 6 weeks ago - Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript - Seeking Alpha
- 6 weeks ago - Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program - Seeking Alpha
- 6 weeks ago - Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants - GlobeNewsWire
- 6 weeks ago - Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump - Benzinga